Phase 3Active, not recruiting
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (I CAN)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)
- Sponsor
- Alexion Pharmaceuticals, Inc. (Industry)
- Enrolment
- 584 enrolled
- Conditions
- Immunoglobulin A Nephropathy; IgAN
- Interventions
- Ravulizumab; Placebo
- Ages
- adults, older adults
- Registry
- NCT06291376
Full record on ClinicalTrials.gov
From the registry
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Primary outcomes
- Change from Baseline in Proteinuria Based on 24-hour Urine Protein Creatinine Ratio (UPCR) at Week 34
- Change from Baseline in Glomerular Filtration Rate (eGFR) at Week 106
History
Study completion expected
Last registry update
Primary completion
Started
Registered